Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | David Reardon, David Peereboom, Burt Nabors, Karen Fink, Surasak Phuphanich, Tom Mikkelsen, Erin Dunbar, Michael Badruddoja, David Schiff, Frank Lieberman, David Tran, Michael Schulder, Nicholas Butowski, Lynn Ashby, Christopher Mortel et.al. | ||||||||||||
Title | PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R?2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS | ||||||||||||
|
|||||||||||||
URL | http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi20.1.abstract?sid=70edd8a6-f8e7-47d1-927b-032ac6c0b974 | ||||||||||||
Abstract Text | Neuro Oncol (2016) 18 (suppl 6): vi20. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|